Assessment of Minipigs as a Non-clinical Model for Screening and Derisking Injection Site Reactions in Clinical Trials
Pharmaceutical Research · 2025
DOI: 10.1007/s11095-025-03907-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Research, 2025. Verfasst von Kaoutar Abbou Oucherif und 4 weiteren Autor:innen. Beteiligte Einrichtung: Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, USA. abbou_oucherif_kaoutar@lilly.com. Hauptthemen laut MEDLINE: Injection Site Reaction, Disease Models, Animal. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Injection site reactions (ISRs), including edema, erythema, pruritus, and pain, impact patient experience and drug tolerability. ISRs are commonly observed and pose challenges in therapeutic development, yet no non-clinical model exists for screening and derisking them before human trials. To fill in this gap, we sought to evaluate the minipig as a non-clinical model for ISRs. METHODS: The minipig model was assessed using six ISR-inducing molecules (positive controls) and two placebos with matching formulations (negative controls). Additionally, to evaluate the physiological similarity between minipigs and humans, we tested whether antihistamine pre-treatment, which is known to reduce ISRs in humans, had a similar effect in minipigs. RESULTS: The minipig model consistently responded to all six positive control molecules, though at higher doses than in humans. Minor ISRs occurred in a quarter of the negative controls but their frequency and/or severity was easily distinguishable from positive controls. Antihistamine pre-treatment effectively reduced ISR severity. CONCLUSION: Our results suggest that the minipig model shows promise for non-clinical screening of high-risk molecules. If a molecule consistently triggers ISRs in the minipig model, phase-appropriate derisking and/or mitigation strategies are warranted. We note that the minipig model is often used for other purposes during pre-clinical subcutaneous drug development; therefore, adding ISR readouts to existing studies would incur minimal operational burden and cost. In summary, our results indicate the potential value of the minipig model in pre-clinical ISR risk assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, USA. abbou_oucherif_kaoutar@lilly.com.
- Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, USA.
Zitieren
APA
Abbou Oucherif, K., Kapur, S., Bei, R., Berens, S., & Brown-Augsburger, P. L. (2025). Assessment of Minipigs as a Non-clinical Model for Screening and Derisking Injection Site Reactions in Clinical Trials. Pharmaceutical Research. https://doi.org/10.1007/s11095-025-03907-2
Vancouver
Abbou Oucherif K, Kapur S, Bei R, Berens S, Brown-Augsburger PL. Assessment of Minipigs as a Non-clinical Model for Screening and Derisking Injection Site Reactions in Clinical Trials. Pharmaceutical Research. 2025. doi:10.1007/s11095-025-03907-2
BibTeX
@article{AbbouOucherif2025,
author = {Abbou Oucherif, Kaoutar and Kapur, Shiven and Bei, Ronghua and Berens, Shawn and Brown-Augsburger, Patricia L},
title = {Assessment of Minipigs as a Non-clinical Model for Screening and Derisking Injection Site Reactions in Clinical Trials},
journal = {Pharmaceutical Research},
year = {2025},
doi = {10.1007/s11095-025-03907-2}
}
EUVIMED